Advanced BioDesign Overview

  • Founded
  • 2010

Founded
  • Status
  • Private

  • Employees
  • 16

Employees
  • Latest Deal Type
  • Later Stage VC

  • (In Progress)
  • Investors
  • 2

Advanced BioDesign General Information

Description

Developer of novel anticancer drugs designed to focus specifically on targeting ALDH as a therapeutic approach for acute myeloid leukemia and other cancers with high unmet medical needs. The company's therapeutic approach focuses on the discovery and production of the recombinant molecules for acute myeloid leukemia and other cancers with high unmet medical needs, enabling institutions in the field of immunology to overcome tumor chemoresistance and to restore or activate endogenous cell death mechanisms in cancer cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Parc Technologique de Lyon, Bâtiment D
  • 655 Allée des Parcs
  • 69800 Saint-Priest
  • France
+33 04 00 00 00 00

Advanced BioDesign Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Advanced BioDesign Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 000.00 In Progress Generating Revenue
3. Grant 15-Nov-2021 00000 000.00 Completed Generating Revenue
2. Later Stage VC 25-Feb-2020 $12.1M $22.3M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 17-Dec-2013 $10.2M $10.2M 000.00 Completed Generating Revenue
To view Advanced BioDesign’s complete valuation and funding history, request access »

Advanced BioDesign Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
ADP D 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
ADP B 00,000 00.000000 0000.00 0000.00 00 0000.00 0.000
To view Advanced BioDesign’s complete cap table history, request access »

Advanced BioDesign Patents

Advanced BioDesign Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3833657-A1 Aminothiolester compounds and uses thereof Pending 31-Jul-2019 00000000000
CA-3027452-A1 Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis Pending 14-Jun-2016 000000000
EP-3469371-A1 Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis Pending 14-Jun-2016 000000000
US-20190169313-A1 Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis Pending 14-Jun-2016 000000000
JP-2019529335-A Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for monitoring apoptosis Pending 14-Jun-2016 C07K16/44
To view Advanced BioDesign’s complete patent history, request access »

Advanced BioDesign Executive Team (3)

Name Title Board Seat Contact Info
Ismail Ceylan Co-Founder, Chief Executive Officer, President & Chairman
Guillaume Martin Co-Founder, Chief Operating Officer & Board Member
Mileidys Perez-Alea Ph.D Co-Founder, Chief Scientific Officer, Scientific Director, Board Member and Member of Scientific Committee.
To view Advanced BioDesign’s complete executive team members history, request access »

Advanced BioDesign Board Members (8)

Name Representing Role Since
Guillaume Martin Advanced BioDesign Co-Founder, Chief Operating Officer & Board Member 000 0000
Ismail Ceylan Advanced BioDesign Co-Founder, Chief Executive Officer, President & Chairman 000 0000
Jacques Simonnet Xerys Invest Board Member 000 0000
Pierre Le Sourd Xerys Invest Board Member 000 0000
You’re viewing 4 of 8 board members. Get the full list »

Advanced BioDesign Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Advanced BioDesign Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bpifrance Sovereign Wealth Fund 000 0000 000000 0
Xerys Invest PE/Buyout Minority 000 0000 000000 0
To view Advanced BioDesign’s complete investors history, request access »